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Summary Four human head and neck xenograft (HNX) tumour lines grown in nude mice and two murine
colon carcinomas (Colon 26 and 38) were tested for their sensitivity to 5-fluorouracil (5-FU) and its prodrug
5'deoxy-5-fluorouridine (Doxifluridine, 5'd-FUR). 5-FU sensitivity at the maximum tolerated dose (MTD)
showed the following pattern; HNX-DU < HNX-KE=HNX-E=HNX-G < Colon 26 << Colon 38. The
sensitivity pattern to 5'd-FUR was: HNX-DU < HNX-G < HNX-E < HNX-KE< Colon 38 < Colon 26.
For HNX-KE, HNX-E and Colon 26 an increase in therapeutic efficacy was observed with 5'd-FUR as
compared to 5-FU; Colon 38 was as sensitive to 5'd-FUR as to 5-FU. Plasma pharmacokinetics of 5'd-FUR
and 5-FU were comparable in normal and nude mice. Metabolism of 5-FU and 5'd-FUR was studied in the
tumours. Conversion of 5'd-FUR to 5-FU was highest in Colon 26 and 15-20 times lower in HNX-DU,
HNX-KE and Colon 38. The Km for 5'd-FUR in all tumours was 1-2mm. Further anabolism of 5-FU to
fluorouridine (FUR) was 5-10 times higher than that of 5-FU to FUR in HNX tumours and 3 times in the
colon tumours. 5-FU conversion to FUMP via FUR had the following pattern: Colon 26 >> HNX-DU >
HNX-G > HNX-E > HNX-KE >> Colon 38; of 5-FU to FdUMP via FUdR: Colon 26 > HNX-
DU=HNX-KE > HNX-E > HNX-G=Colon 38; and that of 5-FU to FUMP catalysed by orotate
phosphoribosyl transferase (OPRT); Colon 26 > Colon 38 > HNX-KE > HNX-E=HNX-DU=HNX-G.
Only those tumours with a relatively high activity of OPRT were sensitive to 5'd-FUR. Colon 26, which has a
very high rate of pyrimidine nucleoside phosphorylase, showed a relatively high increase in the therapeutic
efficacy. It is concluded that a low rate of pyrimidine nucleoside phosphorylase is enough to convert 5'd-FUR
to 5-FU; further anabolism of 5-FU catalysed by OPRT may be limiting and explain the differential
sensitivity.
Fluoropyrimidines are widely used for the treatment of solid
tumours, such as breast, colorectal and head and neck
cancer. The prodrug 5'd-FUR (5'-deoxy-5-fluorouridine,
Doxifluridine) cannot be converted directly to the nucleotide
level due to the presence of a 5-deoxy-ribose moiety and
needs to be converted to 5-FU (5-fluorouracil) (Figure 1) for
its activation (Armstrong et al., 1980, 1981, 1983a; Ishitsuka
et al., 1980; Hartmann & Matter, 1982). 5'd-FUR is
moderately active in patients (20-30% responders) with
various types of tumours (Abele et al., 1984; Alberto et al.,
1986, 1987; Hurteloup et al., 1986) and mice (Armstrong &
Diasio, 1980; Bollag & Hartmann, 1980; Ishitsuka et al.,
1980; Hartmann & Matter, 1982). Plasma level of 5-FU are
usually 5-20% of those of 5'd-FUR at a molar level and 5-
FU mimics 5'd-FUR pharmacokinetics (Sommadossi et al.,
PRPP FUMP other nucleotides
ADP*-.
43
5-FU ATP__; Pi
2 Rib-1-P FUR
5dRib-1-P
5'dFUR
Figure 1 Metabolism of 5'd-FUR and 5-FU. The enzymes
catalyzing these reactions are: 1, OPRT; 2, pyrimidine nucleoside
phosphorylases; 3, 5'nucleotidase and phosphatases; 4, uridine
kinase.
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1983; De Bruijn et al., 1985). In patients peak levels of 5-FU
after injection of 15g 5'd-FUR m-2 were 100-200gM
(Sommadossi et al., 1983; De Bruijn et al., 1985), which are
lower than observed after injection of 500mg 5-FU m 2
(Kok et al., 1984).
The human xenograft model has a potential unique value
in screening and selecting new drugs for clinical trials
(Winograd et al., 1987). We have developed a panel of head
and neck cancer xenograft (HNX) tumour lines in order to
select compounds for phase II trials with head and neck
cancer patients. With drugs such as cisplatin and bleomycin
a number of lines responded but with antimetabolites such
as methotrexate and 5-FU hardly any activity was found in
14 and 7 lines, respectively (Braakhuis et al., 1983, 1988).
Insensitivity to methotrexate was not related to an over-
production of dihydrofolate reductase (Braakhuis et al.,
1985). However, another antimetabolite, 5-aza-2'-deoxy-
cytidine, is active in this model (Braakhuis et al., 1986). Up
to now no biochemical evaluation of HNX cancer lines in
relation to sensitivity to fluoropyrimidines has been
performed.
Activation of 5'd-FUR to 5-FU may occur selectively in
tumour cells compared to normal cells (Armstrong & Diasio,
1981). The activity of pyrimidine nucleoside phosphorylase
appears to be related to the toxicity of 5'd-FUR (Armstrong
et al., 1981, 1983a; Hartmann & Matter, 1982; Ishitsuka et
al., 1980) but a strict correlation has not been demonstrated
(Hartmann & Matter, 1982; Peters et al., 1986a). Cells with a
very low activity of pyrimidine nucleoside phosphorylase
showed a low sensitivity to 5'd-FUR, but cell lines with a
very high activity were not the most sensitive cell lines. We
postulated that although sufficient conversion of 5'd-FUR to
5-FU is essential for a cell to be sensitive to 5'd-FUR, this is
not the only critical factor which determines the activity of
5'd-FUR (Peters et al., 1986a). Further activation of the 5-
FU formed from 5'd-FUR appeared to be essential. A cell
line in which the direct conversion of 5-FU to FUMP (5-
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fluorouridine-5'-monophosphate) plays an important role
appeared to be very sensitive to 5'd-FUR (Peters et al.,
1986a). In this cell line 5'd-FUR was also able to decrease
levels of 5-phosphoribosyl-l-pyrophosphate (PRPP) (Peters
et al., 1985). The other pathways for activation of 5-FU
(Figure 1) appear to play a less important role in the activity
of 5'd-FUR, e.g. the concentration of 2-deoxyribose-l-
phosphate (dRib-I-P) is negligible under physiological
concentrations (Barankiewicz & Henderson, 1977; Peters et
al., 1987a). The role of the various enzymes in drug
activation and thus in the relation with antitumour activity
of 5-FU and 5'd-FUR can be studied by their measurement
with the analogue substrate 5-FU (Peters et al., 1986a).
In order to know whether 5-FU resistance could be
overcome by administration of 5'd-FUR we attempted to
correlate the sensitivity of tumour lines to fluoropyrimidines
and the biochemistry of the drugs in each line, four human
tumour xenografts and two murine colon carcinomas. We
measured the activities of enzymes involved in the activation
of 5'd-FUR and 5-FU. In addition we measured plasma
pharmacokinetics of 5'd-FUR and 5-FU. The results
demonstrated that antitumour activity of 5'd-FUR not only
depends on the rate of conversion to 5-FU but also on the
further metabolism of 5-FU. The results also demonstrate
that sensitivity of 5-FU resistant human head and neck
tumours may be enhanced by modulation of the activation
pathway of 5-FU.
Materials and methods
Chemicals
5-FU and 5'd-FUR were obtained from Hoffmann-La
Roche (Mijdrecht, The Netherlands). 5-FU was formulated
as described previously (Peters et al., 1987b); 5'd-FUR was
obtained as a powder and solubilised just before injection as
a 100mgml-l solution. Pyrimidines and fluoropyrimidines
for biochemical purposes were purchased from Sigma
Chemical Co. (St Louis, MO, USA). PRPP was obtained
from Boehringer (Mannheim, FRG). Plastic sheets precoated
with 0.1 mm polyethyleneimine cellulose were obtained from
Merck (Darmstadt, FRG). 6-14C-5-FU was obtained from
the Radiochemical Centre (Amersham, UK). All other
chemicals were from standard analytical quality.
Tumours
The head and neck tumour lines were established from
tumours from untreated patients and maintained in female
BIO.LP/Cpb nude mice as described previously (Braakhuis
et al., 1984). The murine colon tumours Colon 26
and Colon 38 were maintained in female Balb/c mice and
C57B1/6 mice, respectively, as described previously (Peters et
al., 1987b). Histological data of the various tumour lines are
summarised in Table I. All mice were obtained from the
animal breeding station 'Centraal Proefdieren Bedrijf-TNO'
(Zeist, The Netherlands). Tumours were passaged by
implanting small fragments (1-5mm3) in the thoracic region
Table I Characteristics of the tumour models
TD
Tumour Histology Site of origin (days)
Human xenografts
HNX-DU Undiff. ca. Hypopharynx 4.2
HNX-KE Poorly diff. s.c.c. Larynx 5.8
HNX-E Moderately diff. s.c.c. Oral cavity 11.0
HNX-G Well diff. s.c.c. Skin 10.0
Murine tumours
Colon 26 Undiff. ca. Colon 1.9
Colon 38 Adenoca. Colon 5.2
Diff., differentiated; ca., carcinoma; s.c.c., squamous cell
carcinoma.
of female mice (about 8 weeks of age; about 20g). Tumour
volume was determined by caliper measurement (length x
width x height x 0.5mm3) twice a week. The volume of
the tumour was calculated relative to that on the first day of
treatment (day 0). Evaluation of the tumour growth delay
was performed as described previously (Braakhuis et al.,
1983; Peters et al., 1987b) by calculation of the growth delay
factor (GDF). The GDF=(TDt-TDc)/TDc where TDt
represents the mean tumour doubling time of tumours from
treated mice and TDc that of control tumours. Mice were
treated weekly by i.p. injections of the drugs. Since the
therapeutic efficacy of 5-FU may be dependent on the time
of administration (Peters et al., 1987b), drugs were always
injected between 4 and 6 p.m. Statistical evaluation was
performed using Student's t test for unpaired samples.
Enzyme assays
Tumours (ranging in size between 200 and 2,000mm3) were
obtained from non-treated mice. Mice were killed either by
ether anaesthesia or by cervical dislocation, which did not
affect enzyme activities. Tumours were removed immediately,
directly frozen in liquid nitrogen, and stored in either liquid
nitrogen or at -800C. Frozen tissues were pulverised using a
micro-dismembrator as described (Peters et al., 1986b),
allowing an excellent extraction of enzyme activities. After
pulverisation the powder was weighed and suspended in
assay buffer (50mM EDTA, pH7.4) at a concentration of 1 g
tissue per 4ml buffer. The suspension was centrifuged at
2,500g (5min, 4°C); and subsequently the supernatant was
centrifuged at 11,000g for 10min. The supernatant was
immediately used for determination of enzyme activities.
Enzyme assays were performed at 37°C in a water bath.
Assays with 5-FU as substrate were performed as described
previously for cultured cells and human tumours (Peters et
al., 1986a,b). Products were separated from the substrate 5-
FU using thin-layer chromatography (Peters et al., 1984).
The reaction time varied between 15 and 60min. All assays
were linear with time and protein. The reaction mixture for
the pyrimidine nucleoside phosphorylase assay contained
0.3-60ig protein, 5mMMgCl2 and the cofactors ribose-l-
phosphate (Rib-I-P) or dRib-1-P at 2.5mm final
concentration. For measurement of nucleotide synthesis
(FUMP and FdUMP (5-fluoro-2'-deoxyuridine-5'-mono-
phosphate) via 5-fluorouridine (FUR) or 2'-deoxy-5-
fluorouridine (FUdR) respectively) catalysed by pyrimidine
nucleoside phosphorylase and subsequently a nucleoside
kinase, more protein (200-650pg) was present in the assay.
In order to prevent breakdown of newly formed nucleotides
by phosphatases we added 15mM 2-glycerol-phosphate to
these assays. ATP was present at 2.5mM and dRib-1-P also
at 2.5mm final concentration. For measurement of direct
conversion of 5-FU to FUMP catalysed by orotate
phosphoribosyl transferase (OPRT) the pentose phosphates
were substituded by 2mM PRPP; 0.6mM oa,fl-methylene-
ADP was present to inhibit 5'-nucleotidases; 200-6504g
protein was present. The reaction was initiated by addition
of radiolabelled 5-FU (final concentration 0.27mM 6-14C-5-
FU with a specificity activity of 4.5mCimmol-1). The
phosphorolysis of 5'd-FUR to 5-FU and that of uridine to
uracil were measured using a recently developed HPLC assay
(Laurensse et al., 1988). The assay was performed with the
11,000g supernatant. The assay mixture (total final volume
200 I) contained 5-100,ug protein and 40mMKH2PO4. The
reaction was initiated by addition of 5'd-FUR (final
concentrations 0.25-2mM) or uridine (final concentration
0.5mM) and stopped by boiling for 3min followed by
chilling on ice. Supernatants were analysed with HPLC
(Laurensse et al., 1988).
Pharmacokinetics
In order to reveal possible differences between 5'd-FUR and
5-FU systemic exposure in nude mice and other mice we
determined plasma levels after i.p. administration ofFLUOROPYRIMIDINES IN HEAD AND NECK CANCER 329
500mgkg-1. Sample pretreatment and HPLC procedures
were described previously (De Bruijn et al., 1985). Blood was
collected by heart puncture and two mice were used for the
following time points; 1, 5, 15, 30, 45, 60 and 90 min. Mean
plasma concentrations of 5'd-FUR were calculated. Area
under curve (AUC) and terminal half-life (ti,z) were
determined by the trapezoidal rule and linear regression
analysis, respectively. Clearance (CL) was determined
according to CL=dose/AUC. For comparison between
concentrations the Kruskal-Wallis test was used.
Results
Toxicity
The maximum tolerated dose (MTD) for 5-FU was
50mgkg-1 in nude mice, and 100mgkg-1 for Balb/c and
C57BI/6 mice. No toxic deaths were observed. Since mice
tolerated 5'd-FUR at a dose which was 8-10 times higher
than 5-FU (Bollag & Hartmann, 1980), we initially used
400mg 5'd-FURkg-' in nude mice and 1,000mgkg-1 in
Balb/c and C57Bl/6 mice. However, the dose of 5'd-FUR
could be increased 20 times to 1,000 and 2,000mgkg-1 in
nude mice and normal mice, respectively, which appeared to
be the MTD. The moderate weight loss (5-10%) was
comparable to that of 5-FU, and was observed only at the
first two of the four courses (Figure 2). In non-tumour-
bearing mice, the weight of the mice returned to initial
values and was followed by normal weight increase. In the
tumour bearing Balb/c mice weight loss was observed after
discontinuation of the treatment, due to cachexia caused by
the tumour. No weight loss was observed in tumour bearing
Balb/c and C57BI/6 mice with 5'd-FUR at doses
dl,O00mgkg- . At a dose of 2,500mgkg-1 three of six
Balb/c mice died. In nude mice the low dose of 400mgkg-1
caused no weight loss.
Antitumour activity
HNX-DU was resistant to 5-FU at 50mgkg-1 and to 5'd-
FUR at 400 and 1,000mgkg-1 (Table II). HNX-KE showed
a slight response to 50mg 5-FUkg-1 and at 400mg5'd-
FURkg 1, but a significant antitumor activity at
1,000mg5'd-FURkg-I (Figure 3). The HNX-G and HNX-E
both showed a slight comparable response to 50mg 5-
FUkg-1 and 400mg5'd-FURkg-1 (Table II). In HNX-E a
better antitumour activity was observed at 1,000mg5'd-
.
03)
-0
0 .0
Q)
a)
a
150-
125-
100-
75- I
0 1o 20 30 40
Days
b
150-
125-
100 -
75
FURkg-1. Higher doses of 5'd-FUR could not be tested in
the HNX-G tumour line due to a lack of growth of this line.
Both murine colon tumour lines were studied at various
doses of 5'd-FUR. Colon 38 was very sensitive to 5-FU
(Figure 4), with several complete responders at 100mgkg-1.
Colon 38 showed a similar sensitivity to 5'd-FUR at
1,000mgkg-1; also at lower doses a good response was
observed (Table III). Colon 26 was initially tested at 800 and
1,000mgkg-1. Tumour-growth delay was comparable to 5-
FU at 100mgkg-1. However, higher doses of 5'd-FUR
could be used without lethal toxicity. At 1,500 and
2,000mgkg-1 antitumour activity was significantly enhanced
compared to the schedules with the lower doses. GDF was
comparable to values which were usually only observed with
the sensitive Colon 38 (Table III).
Enzyme activities
A relatively high Km was observed for 5'd-FUR in all
tumours varying from 0.6 to 2mM (Figure 5), while the
maximal activity with 5'd-FUR varied considerably (Table
IV). The highest activity in Colon 26 was about 50 times
higher than in the tumours with the lowest activity, HNX-
DU and HNX-KE. Uridine phosphorylase, measured at
saturating uridine concentrations (Table IV), had the highest
activity in Colon 26 and the lowest in HNX-KE. Results
were expressed per mg protein, the relative differences based
on wet weight were also comparable. For comparison the
protein content of the tumours is given (Table IV).
Pyrimidine nucleoside phosphorylase with 5-FU as
substrate in the reverse direction (Figure 6) was higher with
dRib-l-P as co-substrate than with Rib-I-P in all tumours;
in the HNX tumours at least 10-fold, but in both colon
tumours only 3-fold (Figure 6). With Rib-I-P the highest
activity was found in Colon 26 and the lowest in HNX-KE
and Colon 38. Among the HNX tumours the highest activity
was observed in HNX-E. With dRib-I-P the pattern was
different, although the highest activity was still present in
Colon 26 and the lowest in Colon 38. However, the activities
in the HNX tumours were all higher than in Colon 38 and
the difference of HNX-E with Colon 26 was less than with
Rib-l-P as co-substrate (Figure 6).
Conversion of 5-FU to either FUMP or FdUMP via FUR
or FUdR, respectively, was measured by supplying ATP at a
physiological concentration in the assay for pyrimidine
nucleoside phosphorylase. Under these conditions an
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Figure 2 Weight loss of mice after treatment with 5'd-FUR (0, control mice; *, treated mice). Values represent means + s.e. and
are of 5-7 mice. Body weight loss in tumour-bearing animals was corrected for the weight of the tumour. Chemotherapy was
started at day 0 and is indicated by arrows. Weight loss of nude mice bearing the other HNX tumour lines was comparable or
less, (a) HNX-KE tumour-bearing nude mice treated with 1,000mgkg-1; (b) Colon 26 tumour-bearing Balb-c treated with
2,000mgkg-1; (c) non-tumour-bearing Balb-c mice treated with 2,000mgkg-1.
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Table II Summary of therapeutic data for the human head and
neck tumour lines
Treatment
Dose Weight
Tumour Drug (mgkg-1) Schedule loss (%) GDF
HNX-DU 5-FU 50 q7d x 2 7.6 0.4
5'd-FUR 400 q7d x 2 none -0.1
5'd-FUR 1,000 q7d x 2 3.6 0.4
HNX-KE 5-FU 50 q7d x 2 3.2 0.8a
5'd-FUR 400 q7d x 2 none 0.6b
5'd-FUR 1,000 q7d x 2 4.2 2.1b
HNX-G 5-FU 50 q7d x 2 6.4 1.Oa
5'd-FUR 400 q7d x 2 3.5 0.6
HNX-E 5-FU 50 q7d x 2 3.8 0.8b
5'd-FUR 400 q7d x 2 none o.gb
5'd-FUR 1,000 q7d x 2 <5 1.3b
Significantly different from untreated animals at the levels: 'O.001 <
P<0.01; bO.01 <P<0.05. No regressions were observed.
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Km values for phosphorylation of FUR (Greenberg et al.,
1977), so the concentration of FUR was not rate-limiting.
The rate of chanelling was measured in the presence of a
phosphatase inhibitor to prevent degradation of newly
formed nucleotide. With Rib-I-P as co-substrate the presence
of this inhibitor resulted in a higher amount of FUMP
(about 1.5-fold) in HNX-KE and HNX-G and in Colon 38;
with dRib-I-P a higher amount of FdUMP was found in
HNX-KE, HNX-G and Colon 26 (about 1.4-fold) and in
Colon 38 (2.7-fold).
Chanelling of 5-FU to FUMP was highest in Colon 26
and very low in Colon 38 (Figure 7). All HNX tumours
showed an at least 10 times higher rate than Colon 38, but
also less than 5% of that in Colon 26. Chanelling of 5-FU
to FdUMP showed a completely different pattern. The
activity was highest in Colon 26 but the difference with the
other tumours was less, the activity in HNX-DU and KE
was 50% of that in Colon 26. The rate of chanelling in the
other three tumour lines was much lower.
Direct conversion of 5-FU catalysed by OPRT with PRPP
as the essential co-substrate was measured in the presence of
a nucleotidase inhibitor; in all tumour lines (except Colon 38
and HNX-KE) this resulted in a higher activity (1.5-2.0-fold)
than in the absence. The highest activity of OPRT was
observed in Colon 26 and Colon 38 (Figure 8); from the
HNX tumours the activity was highest in HNX-KE.
Phamacokinetics
Differences between plasma levels of 5'd-FUR and 5-FU in
mouse strains following i.p. injection of 500mgkg-1 were
not significant (P>0.05). Table V shows data of the AUC,
t', z and CL for nude mice and normal mice. The data of
nude mice are comparable with those of normal mice and
are not suggestive of strain differences as found between
WAG/Rij and Wistar rats (De Bruijn et al., submitted for
publication). 5-FU levels derived from 5'd-FUR were
comparable in both mouse strains, as well as plasma
concentrations of the first breakdown product of 5-FU
5-fluorodihydrouracil (data not shown).
Discussion
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Figure 3 Antitumour activity of 5-FU and 5'd-FUR in HNX-
KE. Values represent means + s.e. of 5-10 tumours.
Chemotherapy is indicated by the arrows. Relative tumour
volumes were plotted until tumour size was 4 times its initial
volume at the start of treatment. (a) 0, control; *, 50mg 5-
FUkg-; @, 400mg 5'd-FURkg-; (b) 0, control; *, 1,000mg
5'd-FURkg- .
estimate of the conversion of 5-FU to the nucleotide will be
obtained (Peters et al., 1986a). This conversion was termed
'chanelling', although the enzymes responsible for these
conversions do not exist in an enzyme complex. The
concentration of FUR in the reacton mixture exceeded the
Patients with inoperable head and neck cancer have only
limited benefit from chemotherapy treatment. Initial
responses are often seen, as with the cisplatin/5-FU
schedule, but enhancement of survival is minimal (Tannock
& Browman, 1986). There is still a need for active drugs for
this type of cancer. An attractive way to select agents for
phase II trials is the use of human xenograft tumour lines
(Braakhuis et al., 1983; Winograd et al., 1987). The present
study demonstrated that for human xenografts resistant to 5-
FU the therapeutic efficacy might be increased by treatment
with the 5-FU produg 5'd-FUR. Also the sensitivity of the
murine colon tumour Colon 26 could be enhanced. The
sensitivity of the 5-FU sensitive Colon 38 was not affected.
Mice tolerated a dose of 5'd-FUR 20 times higher than that
for 5-FU. In addition to this relatively low tissue toxicity the
improved therapeutic efficacy might also be related to the
rate of activation of 5'd-FUR to 5-FU. In Colon 26 the
activity of pyrimidine nucleoside phosphorylase with 5'd-
FUR is up to 15 times higher than in the other tumours.
Furthermore, all sensitive (GDF>2) tumours have a
relatively high activity of OPRT, which might play a key
role in the further activation of 5-FU.
The sensitivity of tumours to 5'd-FUR might be correlated
with pyrimidine nucleoside phosphorylase (Ishitsuka et al.,
1980; Armstrong et al., 1980, 1983a; Hartmann & Matter,
1982) although no strict correlation has been demonstrated
(Hartmann & Matter, 1982; Peters et al., 1986a). This
discrepancy might be related to the role of uridine
phosphorylase in the activation of 5'd-FUR. Uridine
phosphorylase might be responsible for conversion of 5'd-
IUU7
I
1FLUOROPYRIMIDINES IN HEAD AND NECK CANCER 331
a)
E
0
E
G)
(a
I I
l
30 40 50
b
.1 nr% _ IUU -1
10 -
1-
01-J r
0 IFl
10 20
I I T 1-
30 40 50 60
Days
Figure 4 Antitumour activity of 5-FU and 5'd-FUR in Colon 26 and Colon 38. Values represent means +s.e. of 8-12 tumours.
In Colon 26 chemotherapy had to be discontinued due to cachexia caused by the tumours. The relative tumour volumes were
plotted until the median day of death (values are of at least 4 mice). For Colon 38 tumour volumes were plotted until they
reached 2,000mm3. (a) Colon 26: 0, control; * 1,500mg 5'd-FURkg-; *, 2,000mg 5'd-FURkg -. (b) Colon 38: 0, control;
*, 100mgFUkg-1; 0, 1,000mg 5'd-FURkg-1.
Table III Summary of therapeutic data for the colon tumours
Treatment
Dose Weight ILS(C26)
Tumour Drug (mgkg-) Schedule loss (%) CR(38) GDF
Colon 26 5-FU 100 q7d x 2 5.2 161 1.5a
5-FU 250 q7d x 1 12.1 (toxic death)
5'd-FUR 800 q7d x 3 4.3 300 1.7a
5'd-FUR 1,000 q7d x 3 6.2 257 3.9a
5'd-FUR 1,500 q7d x 4 6.8 333 4.5a
5'd-FUR 2,000 q7d x 4 8.0 356 6.6a
Colon 38 5-FU 60 q7d x 4 none none 2.4b
5-FU 100 q7d x 4 2.4 4/18 5.2a
5'd-FUR 600 q7d x 4 none 6/18 4.8a
5'd-FUR 800 q7d x 4 none 6/18 4.4a
5'd-FUR 1,000 q7d x 4 no 2/9 5.5a
ILS: increase in life-span, calculated as T/C%=(median life span treated mice)/
(median life span untreated mice) x 100%; the first day of treatment was used as
day 0. Only for Colon 26 is the ILS given, since C57Bl/6 mice bearing Colon 38
were killed when tumour volume exceeded 2,000mm3. For Colon 38 the number
of complete responders (CR) is given, the GDF is calculated from the remaining
tumours. Significantly ditrerent from untreated animals at the level: 'P<0.001;
b0.001 <P<0.01.
FUR to 5-FU (Ishitsuka et al., 1980) but 5'd-FUR is also a
substrate for thymidine phosphorylase (Siegel & Lin, 1986).
In our studies it appeared that the rate of phosphorolysis of
5'd-FUR did not correlate with that of uridine, and the
pattern of activity was completely different for both
substrates. Actually the activity of pyrimidine nucleoside
phosphorylase with 5'd-FUR correlated with that of 5-FU
and dRib-1-P as substrates. This conversion of 5-FU to
FUdR and the cleavage of FUdR are mainly catalysed by a
thymidine and/or a uridine-deoxyuridine phosphorylase
(Woodman et al., 1980; Peters et al., 1986a). Enzyme kinetics
of pyrimidine nucleoside phosphorylase with 5'd-FUR as a
substrate were comparable to other studies, about mM
(Armstrong & Diasio, 1980; Choong & Lee, 1986; Miwa et
al., 1981), which is much higher than that for uridine (Leyva
et al., 1983; Laurensse et al., 1988) or thymidine (Wataya &
Santi, 1981). So, 5'd-FUR has a low affinity for pyrimidine
phosphorylases and might be a substrate for various
phosphorylases (Woodman et al., 1980; Choong & Lee,
1986).
Resistance of the HNX lines to 5-FU might be related to
several factors, such as a deficient activation of 5-FU,
differences in the inhibition of the target enzyme thymidylate
synthase, high intratumoral levels of thymidine or
deoxyuridine or the incorporation of 5-FU into RNA
(Pinedo & Peters, 1988). However, the mechanism of 5'd-
FUR cytotoxicity is directly analogous to that for 5-FU,
inhibition of thymidylate synthase being the most potent
mechanism (Armstrong et al., 1983b). Thus differences
between effects of 5-FU and 5'd-FUR are most likely related
to activation of 5'd-FUR to 5-FU and subsequently to active
nucleotides.
In this panel of tumours uridine phosphorylase appears
not be be related to the sensitivity of the tumours to 5'd-
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Figure 5 Lineweaver-Burk plots for determination of the Km for 5'd-FUR in the various tumour
representative experiment is shown out of 3-4. v, nmol h- mg protein -.
lines. For each line a
Table IV Activities of pyrimidine nucleoside phosphorylase with 5'd-FUR
and uridine as substrates
5'd-FUR Uridine mg protein per
Tumour line Vmax Km activity mg wet weight
HNX-E 2,300+460 1.16+0.30 179 +68 24.9+2.5
HNX-DU 273 +28 0.80+0.11 124+14 27.8+6.9
HNX-KE 366+54 1.16+0.09 73+6 36.6+2.8
HNX-G 2,565+293 1.02+0.34 94+7 22.8+2.7
Colon 26 9.892+2,097 1.89+0.54 9,040+ 1,525 53.8+9.0
Colon 38 671 +238 2.19+ 1.56 344+65 47.3+ 11.1
Enzyme activities are given as nmol of 5-FU or uracil formed per hper
mg protein, Km is given in mM. Vmax and Km values were determined in
separate tumours. Values are means +s.e. of 3-5 different tumours. For
comparison the protein content of the tumours is given; protein was
determined in the 11,OOOg supernatant using the Biorad dye exclusion
assay.
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Figure 7 Synthesis of FUMP and FdUMP from 5-FU via FUR
or FUdR, respectively. The 'channeling' reaction was measured
with Rib-l-P (filled columns) or dRib-l-P (hatched columns) as
co-substrates in the presence of ATP. Values represent means
+s.e. of 3-5 different tumours.
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Figure 6 Activity of pyrimidine nucleoside phosphorylase with
5-FU as substrate and Rib-I-P (filled columns) or dRib-I-P
(hatched columns) as co-substrate. Values represent means +s.e.
of 3-5 different tumours.
FUR. The very sensitive Colon 38 and Colon 26 have a very
low and high rate of 5'd-FUR phosphorolysis, respectively.
However, the sensitive HNX-KE has a lower activity than
HNX-E and HNX-G. So, other factors than the rate of
phosphorolysis of 5'd-FUR play an important role in the
sensitivity to 5'd-FUR, such as a subsequent
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Figure 8 Activity of OPRI with 5-LU .as substrate and PRP1P
as co-substrate. Values represent meanis + s.e. of 3 5 different
tumours.
Table V Pharmacokinctic paraimeters of 5'd-FUR .and 5-FH
in normal and nude mice
Ptlara111eterl- Comlipounldt Norm'1tal Inice Vudc m/ice
AUC 5'd-FUR 110 130
(nmol min ml ') 5-FU 6.1 6.4
2t (min) 5'd-FUR 30.0 35.0
5-FU 29.0 24.2
CL 5'd-FUR 18.4 15.7
(ml min't kg')
Mice received an i.p. injection of 500mg 5'd-FUR kg '.
Mean plasma concentration time curves from t= 1 to
t=90 min were calculated for two mice per time-point. AUC,
tz land CL were determined by model-independent methods.
phosphorylation to nucleotides and incorporationi into RNA
(Armstrong et al., 1983a). Cory & Cartcr (1982)
demonstrcated that 5-FU and 5'd-FUR are not activated in
the same way in order to show growth-inhibition. Activation
to FdUMP via FUdR is unlikely because of low endogenous
levels of the co-substrate dRib-I-P. Levels of Rib-l-P are
usually high enough for activation of 5-FU to FUMP via
FUR, but this pathway was low in the 5'd-FUR sensitive
Colon 38, high in the 5'd-FUR resistant HNX-DU, and very
high in Colon 26, and might only be important for
Colon 26. However, this way of phosphorylation of 5-FU
formed from 5'd-FUR is unlikely (Peters et al., 1986a,),
which could be partially due to: (a) the presence of the
modified pentose phosphate 5-deoxy-ribose- 1-phosphate
which might compete with the substrate Rib-I-P and (b) an
interference of 5'd-FUR itself with pyrimidine nucleoside
phosphorylase. The only alternative for phosphorylation of
5-FU will be direct conversion to FUMP. The substrate for
this reaction, PRPP, could be decreased by 5'd-FUR only in
WiDr cells, the most sensitive cell line in this panel (Peters et
alt., 1985, 1986a). WiDr cells had a relatively high activity of
OPRT both with the analogue substrate 5-FU and the
natural substrate orotic acid (Peters et al., 1985, 1986ai). In
the present panel the most sensitive lines Colon 26, Colon 38
and HNX-KE have a relatively high activity of OPRT with
5-FU. So, only tumours with a sufficient capacity to convert
5'd-FUR to 5-FU and a subsequent effective conversion of
5-FU to nucleotides may be sensitive to 5'd-FUR.
Differences between in iio drug handling of different
mouse strains have not been observed and therefore extra-
tumoral exposure is considered to be comparable. Thus.
differences between 5'd-FUR effects on tumours in nude and
normal mice cannot be explained by differences in extra-
tumoral drug handling.
5--FU resistant tumours may not use efficiently the
pathway catalysed by OPRT for 5-FU activation, possibly
due to a low availability of PRPP or a high activity of
pyrimidine nucleoside phosphorylase. Thus inhibition of
pyrimidine nucleoside phosphorylase may lead to ac more
efficient use of the OPRT pathway, and therapy of 5-FU
resistant tumours, such as several head and neck and colon
cancers, might be improved by an efficient use of the OPRT
pathway. Biochemical modulators, such as inhibitors of
uridine phosphorylase may prove to be potential chemo-
therapeutic agents (Siegel & Lin, 1986).
Several human colon tumours have a relatively high
activity of OPRT compared to adjacent normal mucosal
tissue (Peters et atl., 1986b). So, colorectal cancer might be an
attractive tumour type to be treated with 5'd-FUR, and
recent results showed an improved therapeutic effect in
rectosigmoid colorectal cancer (Abele et al., 1988). An
advantage over 5-FU might be expected since the 5-FU
sensitive tumours will also respond to 5'd-FUR while some
5-FU resistant or relatively resistant tumours might show a
better response. Other schedules or ways of administration
might be explored to circumvent the observed neurotoxicity.
In conclusion, a better therapeutic efficacy was achieved
with 5'd-FUR for several lines than with 5-FU. The
enhanced sensitivity to 5'd-FUR might not strictly be related
to its rate of conversion to 5-FU. Although a certain amount
of activity is essential to convert 5'd-FUR to 5-FU, further
metabolism to nucleotides might be limiting. This might lead
to an improved therapeutic efficacy of 5'd-FUR compared to
5-FU in tumours with a high OPRT activity such as HNX-
KE and Colon 26. These findings indicate that lurther
studies aiming at enhancing of therapeutic efficacy observed
with 5'd-FUR are warranted.
This work was supported by the Netherlands Cancer Foundation
(Koninlgin Wilhelmina Fonds) by grants IKA 83-16 and AUKC-VLU
82-1 1. and by Hoffinann-La Roche, Mijdrecht. The Netherlands. We
also thank Dr J. van Dijk, Mrs M. Bagniay anid Mr E.J. Schoevers
for their contributions. Dr G.J. Peters is a senior research fellow of
the Royal Netherlands Academy of Sciences.
References
ABELE. R., KAPLAN, E., GROSSENBACHER. R., SCHMIDT, H.J. &
C'AVALLI, F. (1984). Phasc 11 study of doxifluridine in advIanced
squamous ccll carcinom-a of the head and neck. Eur. J. Cancer
Clini. Oncol., 20, 333.
ALBERTO, P., MERMILLOD, B., GERMANO. C. & 6 others (1988). A
randomized comparison of Doxifluridinie and fluorouracil in
colorectal carcinoma. Eur. J. Cancer Clin,. Oncol., 24, 559.
ARMSTRONG, R.D. & DIASIO, R.B. (1980). Metabolism and
biological activity of 5'-deoxy-5-fluorouridine. C('ineer Res., 40,
3333.
ARMSTRONG. R.D. & DIASIO, R.B. (1981). Selective activatioin of 5'-
deoxy-5-fluorouridince by tumor cells as a basis for an improved
therapeutic index. Cancre Res., 41, 4891.
ARMSTRONG. R.D.. GESMONDE. J., WU. T. & CADMAN. E. (1983ci).
Cytotoxic activity of 5'-deoxy-5-fluorouridine in cultured human
tumors. Cancer Trecat. Rep., 67, 541.
ARMSTRONG. R.D., CONNOLLY, K.M.. KAPLAN. A.M. & CADMAN.
E. (1983h). Mechanism of cytotoxic activity of 5'-deoxy-5-
fluorouridine. Cancter Chenmother. Pharm(acol., 11, 102.334 G.J. PETERS et al.
BARANKIEWICZ, J. & HENDERSON, J.F. (1977). Determination of
ribose 1-phosphate in ascites cells. Biochem. Med., 17, 45.
BOLLAG, W. & HARTMANN, H.R. (1980). Tumor growth inhibitory
effects of a new fluorouracil derivative: 5'-deoxy-5-fluorouridine.
Eur. J. Cancer, 16, 427.
BRAAKHUIS, B.J.M., SCHOEVERS, E.J., HEINERMAN, E.C.M.,
SNEEUWLOPER, G. & SNOW, G.B. (1983). Chemotherapy of
human head and neck cancer xenografts with three clinically
active drugs: cis-platinum, bleomycin and methotrexate, Br. J.
Cancer, 48, 711.
BRAAKHUIS, B.J.M., SNEEUWLOPER, G. & SNOW, G.B. (1984). The
potential of the nude mouse xenograft model for the study of
head and neck cancer. Arch. Otorhinolaryngol., 239, 69.
BRAAKHUIS, B.J.M., LEYVA, A., SCHOEVERS, E.J., BOERRIGTER,
G.H., SCHORNAGEL, J.H. & SNOW, G.B. (1985). Lack of effect of
methotrexate on human head and neck tumours transplanted in
aythmic, nude mice. Acta Otolaryngol., 99, 208.
BRAAKHUIS, B.J.M., LEYVA. A., PINEDO, H.M. & SNOW, G.B. (1986).
Antitumour effect of 5-aza-2'deoxycytidine in human head and
neck cancer xenografts. Proc. Am. Assoc. Cancer Res., 27, 299.
BRAAKHUIS, B.J.M. & SNOW, G.B. (1988). Activity of Conventional
Drugs in Head and Neck Cancer Xenografts. ESO Monographs,
Human Xenografts in Anticancer Drug Development, p. 37.
Springer Verlag: Heidelberg.
CHOONG, Y.S. & LEE, S.P. (1985). The degradation of 5'-deoxy-5-
fluorouridine by pyrimidine nucleoside phosphorylase in normal
and cancer tissues. Clin. Chim. Acta, 149, 175.
CORY, J.G. & CARTER, G.L. (1982). Evidence that 5'-deoxy-5-
fluorouridine may not be activated by the same mechanism as 5-
fluorouracil. Biochem. Pharmacol., 31, 2841.
DE BRUIJN, E.A., VAN OOSTEROM, A.T., TJADEN, U.R., VAN
REEUWIJK, H.J.E.M. & PINEDO, H.M. (1985). Pharmacology of
5'-deoxy-5-fluorouridine in patients with resistant ovarian cancer.
Cancer Res., 45, 5931.
GREENBERG, N., SCHUMM, D.E. & WEBB, T.E. (1977). Uridine
kinase activities and pyrimidine nucleoside phosphorylation in
fluoropyrimidine-sensitive and resistance cell lines of the
Novikoff hepatoma. Biochem. J., 164, 379.
HARTMANN, H.R. & MATTER, A. (1982). Antiproliferative action of
a novel fluorinated uridine analog, 5'-deoxy-5-fluorouridine,
measured in vitro and in vivo on four different murine cell lines.
Cancer Res., 42, 2412.
HURTELOUP, P., ARMAND, J.P., CAPPELAERE, P. & 16 others
(1986). Phase II Clinical evaluation of doxifluridine. Cancer
Treat. Rep., 70, 731.
ISHITSUKA, H., MIWA, M., TAKEMOTO, K., FUKUOKA, K., ITOGA,
A. & MARUYAMA, H.B. (1980). Role of uridine phosphorylase
for antitumor activity of 5'-deoxy-5-fluorouridine. Gann, 71, 112.
KOK, R.M., DE JONG, A.P.J.M., VAN GROENINGEN, C.J., PETERS, G.J.
& LANKELMA, J. (1984). Highly sensitive determination of 5-
fluorouracil in human plasma by capillary gas chromatography
and negative ion chemical ionization mass spectrometry. J.
Chi-rom?atogr., 343, 59.
LAURENSSE, E., PINEDO, H.M. & PETERS, G.J. (1988). A sensitive
non-radioactive assay for pyrimidine nucleoside phosphorylase
using reversed phase high-performance chromatography. Clin.
Chim. Acta, 178, 71.
LEYVA, A., KRAAL, I., LANKELMA, J., DELEMARRE, J.F.M. &
PINEDO, H.M. (1983). High uridine phosphorylase activity in
human melanoma. Anticancer Res., 3, 227.
MIWA, M., NAKAMURA, J. & ISHITSUKA, H. (1981). A simple and
convenient assay method for phosphorolysis of 5'-deoxy-5-
fluorouridine. Gann, 72, 965.
PETERS, G.J., LAURENSSE, E., LANKELMA, J., LEYVA, A. &
PINEDO, H.M. (1984). Separation of several 5-fluorouracil
metabolites in various melanoma cell lines. Evidence for the
synthesis of 5-fluorouracil-nucleotide sugars. Eur. J. Cancer Clin.
Oncol., 20, 1425.
PETERS, G.J., LAURENSSE, E., LEYVA, A. & PINEDO, H.M. (1985).
The concentration of 5-phosphoribosyl-1-pyrophosphate in
monolayer cells and the effect of various pyrimidine anti-
metabolites. Int. J. Biochem., 17, 95.
PETERS, G.J., LAURENSSE, E., LEYVA, A., LANKELMA, J. &
PINEDO, H.M. (1986a). Sensitivity of human, murine and rat cells
to 5-fluorouracil and 5'deoxy-5-fluorouridine in relation to drug-
metabolizing enzymes. Cancer Res., 46, 20.
PETERS, G.J., LAURENSSE, E., LEYVA, A. & PINEDO, H.M. (1986b).
Tissue homogenization using a microdismembrator for the
measurement of enzyme activities. Clin. Chim. Acta, 158, 193.
PETERS, G.J., LAURENSSE, E., LEYVA, A. & PINEDO, H.M. (1987a).
Purine nucleosides as cell-specific modulators of 5-fluorouracil
metabolism and cytotoxity. Eur. J. Cancer Clin. Oncol., 23, 1869.
PETERS, G.J., VAN DIJK, J., NADAL, J.C., VAN GROENINGEN, C.J.,
LANKELMA, J. & PINEDO, H.M. (1987b). Diurnal variation in the
therapeutic efficacy of 5-fluorouracil against murine colon
cancer. In Vivo, 1, 113.
PINEDO, H.M. & PETERS, G.J. (1988), 5-Fluorouracil: Biochemistry
and pharmacology. J. Clin. Oncol., 6, 1653.
SIEGEL, S.A. & LIN, T.-S. (1986). Inhibitors of uridine phosphorylase:
Potential chemotherapeutic agents. Drugs Future, 11, 961.
SOMMADOSSI, J.-P., AUBERT, C., CANO, J.-P., GOUVEIA, J.,
RIBAUD, P. & MATHE, G. (1983). Kinetics and metabolism of a
new fluoropyrimidine, 5'-deoxy-5-fluorouridine in humans.
Cancer Res., 43, 930.
TANNOCK, I.F. & BROWMAN, G. (1986). Lack of evidence for a role
of chemotherapy in the routine management of locally advanced
head and neck cancer. J. Clin. Oncol., 4, 1121.
WATAYA, Y., SANTI, D.V. (1981). Continuous spectrophotometric
assay of thymidine phosphorylase using 5-nitro-2'-deoxyuridine
as substrate. Anal. Biochem., 112, 96.
WINOGRAD, B., BOVEN, E., LOBBEZOO, M.W. & PINEDO, H.M.
(1987). Human xenografts in the nude mice and their value as
test models in anticancer drug development. In Vivo, 1, 1.
WOODMAN, P.W., SARIL, A.M. & HEIDELBERGER, C. (1980).
Specificity of pyrimidine nucleoside phosphorylases and the
phosphorylysis of 5-fluoro-2'-deoxyuridine. Cancer Res., 40, 507.